相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
Hye Joung Choi et al.
GYNECOLOGIC ONCOLOGY (2019)
Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer
Jan Remsik et al.
BRITISH JOURNAL OF CANCER (2018)
Cancer stem cell in breast cancer therapeutic resistance
Xupeng Bai et al.
CANCER TREATMENT REVIEWS (2018)
Abrogation of glutathione peroxidase-1 drives EMT and chemoresistance in pancreatic cancer by activating ROS-mediated Akt/GSK3β/Snail signaling
Qingcai Meng et al.
ONCOGENE (2018)
EMT and stemness: flexible processes tuned by alternative splicing in development and cancer progression
Davide Pradella et al.
MOLECULAR CANCER (2017)
PI3K/ AKT-mediated upregulation of WDR5 promotes colorectal cancer metastasis by directly targeting ZNF407
Xin Tan et al.
CELL DEATH & DISEASE (2017)
PGC1α induced by reactive oxygen species contributes to chemoresistance of ovarian cancer cells
Boyun Kim et al.
ONCOTARGET (2017)
Identification and characterization of CD133(+) CD44(+) cancer stem cells from human laryngeal squamous cell carcinoma cell lines
Jue Wang et al.
JOURNAL OF CANCER (2017)
Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK
Girijesh Kumar Patel et al.
BRITISH JOURNAL OF CANCER (2017)
Dactolisib (NVP-BEZ235) toxicity in murine brain tumour models
I. A. Netland et al.
BMC CANCER (2016)
Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer
Junli Deng et al.
ONCOTARGET (2016)
Strategy to Suppress Oxidative Damage-Induced Neurotoxicity in PC12 Cells by Curcumin: the Role of ROS-Mediated DNA Damage and the MAPK and AKT Pathways
Xiao-yan Fu et al.
MOLECULAR NEUROBIOLOGY (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells
Jiezhong Chen et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2015)
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
Ben Davidson et al.
HUMAN PATHOLOGY (2015)
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
Johanna C. Bendell et al.
INVESTIGATIONAL NEW DRUGS (2015)
Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway
Hao Wang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Yu Wang et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden
Khalid Abubaker et al.
FRONTIERS IN ONCOLOGY (2014)
Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance
L. Chang et al.
CELL DEATH & DISEASE (2013)
EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer
Alexandria M. Haslehurst et al.
BMC CANCER (2012)
Spatiotemporal Regulation of Epithelial-Mesenchymal Transition Is Essential for Squamous Cell Carcinoma Metastasis
Jeff H. Tsai et al.
CANCER CELL (2012)
In Vitro and In Vivo Prostate Cancer Metastasis and Chemoresistance Can Be Modulated by Expression of either CD44 or CD147
Jingli Hao et al.
PLOS ONE (2012)
Recent Progress in the Diagnosis and Treatment of Ovarian Cancer
Danijela Jelovac et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Aldehyde Dehydrogenase in Combination with CD133 Defines Angiogenic Ovarian Cancer Stem Cells That Portend Poor Patient Survival
Ines A. Silva et al.
CANCER RESEARCH (2011)
Quiescent, Slow-Cycling StemCell Populations in Cancer: A Review of the Evidence and Discussion of Significance
Nathan Moore et al.
JOURNAL OF ONCOLOGY (2011)
Combination Therapy Targeting Both Tumor-Initiating and Differentiated Cell Populations in Prostate Carcinoma
Anna Dubrovska et al.
CLINICAL CANCER RESEARCH (2010)
The therapeutic promise of the cancer stem cell concept
Natasha Y. Frank et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells
M-Q Gao et al.
ONCOGENE (2010)
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes
Joseph H. Taube et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics
Xiaolong Wei et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling
Christina Gewinner et al.
CANCER CELL (2009)
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery et al.
CELL (2009)
Reversal of P-glycoprotein-mediated multi-drug resistance by the E3 ubiquitin ligase Cbl-b in human gastric adenocarcinoma cells
Ye Zhang et al.
JOURNAL OF PATHOLOGY (2009)
The epithelial-mesenchymal transition generates cells with properties of stem cells
Sendurai A. Mani et al.
CELL (2008)
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
John D. Carpten et al.
NATURE (2007)
Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data
Hui-Juan Yang et al.
BMC CANCER (2006)
Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment
SD Westfall et al.
MOLECULAR CANCER THERAPEUTICS (2005)
G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells
N Gao et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2004)
分享论文
